aTyr Pharma ATYR Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about aTyr Pharma's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is aTyr Pharma's accretion (amortization) of discounts and premiums, investments?
- aTyr Pharma (ATYR) reported accretion (amortization) of discounts and premiums, investments of $255K in Q1 2026.
- How has aTyr Pharma's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- aTyr Pharma's accretion (amortization) of discounts and premiums, investments decreased by 51.2% year-over-year, from $523K to $255K.
- What is the long-term trend for aTyr Pharma's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), aTyr Pharma's accretion (amortization) of discounts and premiums, investments has grown at a 50.0% compound annual growth rate (CAGR), from -$366K to $1.85M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income resulting from the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the systematic recognition of the difference between the purchase price and the maturity value of investment securities over their holding period. This adjustment is essential for reconciling net income to net cash provided by operating activities by removing non-cash yield components.